The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).

Philippe L.  Bedard

Consulting or Advisory Role - Amgen; BMS (Inst); Gilead Sciences; Lilly; Merck; Pfizer (Inst); Seagen

Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)

Melissa Kate  Accordino

Honoraria - Incrowd; M3; Massive Bio; Sermo

Other Relationship - Onclive

Andres  Cervantes

Consulting or Advisory Role - Amgen (Inst); Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst); Transgene (Inst)

Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)

Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open

Valentina  Gambardella

Research Funding - Roche; Roche

Erika P.  Hamilton

Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)

Antoine  Italiano

Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche

Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche

Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche

Patents, Royalties, Other Intellectual Property - BMS

Dejan  Juric

Research Funding - Roche; Roche

Kevin  Kalinsky

Stock and Other Ownership Interests  - Array BioPharma (I); GRAIL (I); Pfizer (I)

Consulting or Advisory Role - 4D Pharma; AstraZeneca; bioTheranostics; Cyclacel; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; immunomedics; Ipsen; Lilly; Merck; mersana; Novartis; Oncosec; pfizer; Puma Biotechnology; Seagen

Speakers' Bureau - Lilly

Research Funding - Acetylon Pharmaceuticals (Inst); Amgen (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Zeno Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer

Other Relationship - Genentech; Immunomedics

Ian E.  Krop

Employment - Freeline Therapeutics (I); PureTech (I)

Leadership - Freeline Therapeutics (I); PureTech (I)

Stock and Other Ownership Interests  - Freeline Therapeutics (I); PureTech (I)

Honoraria - AstraZeneca; Genentech/Roche

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seagen

Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)

Mafalda  Oliveira

Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen

Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen

Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)

Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche

Cristina  Saura

Consulting or Advisory Role - AstraZeneca; Ax's Consulting; Byondis; Daiichi Sankyo; Eisai; Exact Sciences; Exeter Pharmaceuticals; ISSECAM; MediTech; Merck Sharp & Dohme; Novartis; Pfizer; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; Roche; Sanofi/Aventis; Seagen; Zymeworks

Research Funding - Aragon Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim España (Inst); Bristol-Myers Squibb (BMS) (Inst); Cytomx Therapeutics (Inst); Daiichi Sankyo (Inst); Genentech (Inst); German Breast Group (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); International Breast Cancer Study Group (Inst); Lilly (Inst); Macrogenics (Inst); MedSIR (Inst); Menarini (Inst); Merus (Inst); Millennium (Inst); Millennium (Inst); Novartis Farmacéutica (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Roche

Peter  Schmid

Employment - Roche (I)

Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Merck; Novartis; Pfizer; Puma Biotechnology; Roche

Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation; Novartis (Inst); Oncogenex (Inst); Roche (Inst)

Nicholas C.  Turner

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals

Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)

Andreea  Varga

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca/MedImmune

Noopur  Shankar

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Roche

Jennifer  Schutzman

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Roche

Stephanie  Royer-Joo

Employment - Genentech

Stock and Other Ownership Interests  - Roche

Research Funding - Roche

Miguel Valero  Martin

Employment - Roche

Stock and Other Ownership Interests  - Roche

Research Funding - Roche

Komal L.  Jhaveri

Consulting or Advisory Role - Abbvie; AstraZeneca; Biotheranostics; BluePrint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Intellisphere; Jounce therapeutics; Lilly; Novartis; Pfizer; Sanofi; Seagen; Sun Pharma Advanced Research Company; Synthon; Taiho Oncology

Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Puma Biotechnology (Inst); VelosBio/Merck (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Intellisphere; Jounce Therapeutics; Pfizer; Taiho Pharmaceutical